Sign In
Buy CORT
$72.65
+1.45 (+2.04%)
At Close: Jun 03, 2026
Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Stockholders to Connect
10:30am, Tuesday, 25'th Feb 2025
NEW YORK CITY, NY / ACCESS Newswire / February 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Corcept Therapeutics Incorporated ("Corcept" o
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call
04:05pm, Wednesday, 12'th Feb 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2024 financial results and provide a corporate updat
Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock?
09:40am, Friday, 31'st Jan 2025
Corcept (CORT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
09:05am, Friday, 31'st Jan 2025
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio.
All You Need to Know About Corcept (CORT) Rating Upgrade to Strong Buy
01:05pm, Wednesday, 29'th Jan 2025
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Big Money Keeps Buying Corcept
07:37am, Wednesday, 29'th Jan 2025
Corcept Therapeutics Incorporated (CORT) shares rise on treatment advances, Big Money buys.
Buy These 5 Stocks With Recent Price Strength Amid a Volatile January
07:36am, Wednesday, 29'th Jan 2025
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are OPFI, CORT, DXPE, PPTA, GHM.
Is Corcept (CORT) a Solid Growth Stock? 3 Reasons to Think "Yes"
01:46pm, Friday, 24'th Jan 2025
Corcept (CORT) possesses solid growth attributes, which could help it handily outperform the market.
Kuehn Law Encourages Investors of Corcept Therapeutics Inc. to Contact Law Firm
11:00am, Friday, 24'th Jan 2025
NEW YORK , Jan. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Inc. (NASDAQ: CORT) breache
Corcept Therapeutics Incorporated (CORT) Hit a 52 Week High, Can the Run Continue?
10:16am, Friday, 24'th Jan 2025
Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Corcept Therapeutics Generating Strong Revenue And Profit Growth
02:03pm, Wednesday, 22'nd Jan 2025
Corcept's sole drug, Korlym, treats Cushing Syndrome, a more prevalent condition than previously known, driving strong revenue and profit growth. A new market for Corcept's medications, diabetics, is
Medical Stock Soars To Highs As Cortisol Screening Grows
11:35am, Wednesday, 22'nd Jan 2025
Corcept Therapeutics makes drugs that modulate cortisol. The post Medical Stock Soars To Highs As Cortisol Screening Grows appeared first on Investor's Business Daily.
Corcept Submits Application for Another Cushing's Syndrome Drug
02:56pm, Tuesday, 31'st Dec 2024
CORT makes pipeline progress with the submission of a new drug application for relacorilant to treat patients with endogenous hypercortisolism.
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism
05:15pm, Monday, 30'th Dec 2024
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
